riociguat 0.5 MG Oral Tablet

Known as: RIOCIGUAT 0.5MG TAB, RIOCIGUAT 0.5MG TAB,UD [VA Product], RIOCIGUAT 0.5MG TAB UD

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2015

2015

The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)

M. HuntgeburthJ. Kießling S. Rosenkranz
BMC Pharmacology and Toxicology
2015
Corpus ID: 26388594

Background Raynaud’s phenomenon (RP) is a coldor stress-triggered digital ischemia caused by vasoconstriction in the digital…

2015

2015

РИОЦИГУАТ – ПЕРВЫЙ ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ИННОВАЦИОННОГО КЛАССА СТИМУЛЯТОРОВ ГУАНИЛАТЦИКЛАЗЫ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ ЛЕГОЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ

Summary Pulmonary arterial hypertension (PAH) drug therapy including prostanoids, endothelin receptor antagonists, type 5…

2013

2013

Riociguat zur Therapie der inoperablen chronisch thromboembolischen pulmonalen Hypertonie: Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie (CHEST-1)

H. GhofraniF. Grimminger M. M. Hoeper
2013
Corpus ID: 75792326

2013

2013

Neuer Weg zur Therapie der pulmonalen Hypertonie

S. Meinrenken
2013
Corpus ID: 75940243

Fur die Therapie der pulmonalen Hypertonie (PH) steht mit den loslichen Guanylatcyclase-Stimulatoren eine neue Gruppe von…